Department of Rheumatology and Immunology, Peking University People's Hospital, BeijingChina.
Department of Rheumatology and Immunology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, HenanChina.
Rheumatology (Oxford). 2020 Aug 1;59(8):2115-2123. doi: 10.1093/rheumatology/kez669.
Patients with IgG4-related disease (IgG4-RD) typically respond well to initial glucocorticoid therapy, but always relapse with tapered or maintenance dosage of steroid. We aimed to identify the risk factors for relapse of IgG4-RD and explore the impact of active intervention on the serologically unstable condition.
We performed a retrospective study of 277 IgG4-RD patients at Peking University People's Hospital from February 2012 through February 2019. They were all followed for >4 months. The primary outcome was patient relapse. Data on recurrence of IgG4-RD symptoms, laboratory and image findings were recorded, along with information on treatment in the serologically unstable condition.
The cumulative relapse rate was 12.86%, 27.84% and 36.1% at 12, 24 and 36 months, respectively. Younger age at onset, younger age at diagnosis, longer time from diagnosis to treatment and history of allergy were associated with relapse. Identified independent risk factors were longer time from diagnosis to treatment and history of allergy. When serum IgG4 level was 20%, 50% or 100% higher than that of the remission period, similar percentages of patients finally relapsed, regardless of whether they were in the immunosuppression intensified or non-intensified group. Median duration from serum IgG4 level instability to relapse in the intensified and non-intensified group was not statistically different.
The risk factors of relapse were longer time from diagnosis to treatment and history of allergy. Intervention in the serologically unstable condition was not helpful for reducing relapse rate.
IgG4 相关疾病(IgG4-RD)患者对初始糖皮质激素治疗反应良好,但在类固醇逐渐减量或维持剂量时总会复发。我们旨在确定 IgG4-RD 复发的危险因素,并探讨主动干预对血清学不稳定状态的影响。
我们对 2012 年 2 月至 2019 年 2 月期间在北京大学人民医院就诊的 277 例 IgG4-RD 患者进行了回顾性研究。所有患者均随访>4 个月。主要结局为患者复发。记录 IgG4-RD 症状、实验室和影像学发现的复发情况,以及血清学不稳定状态下的治疗信息。
12、24 和 36 个月时的累积复发率分别为 12.86%、27.84%和 36.1%。发病年龄较小、诊断年龄较小、从诊断到治疗的时间较长和过敏史与复发相关。确定的独立危险因素是从诊断到治疗的时间较长和过敏史。当血清 IgG4 水平比缓解期高 20%、50%或 100%时,无论是否处于免疫抑制强化或非强化组,最终复发的患者比例相似。强化组和非强化组从血清 IgG4 水平不稳定到复发的中位时间无统计学差异。
复发的危险因素是从诊断到治疗的时间较长和过敏史。对血清学不稳定状态的干预无助于降低复发率。